Skip navigation

Strengthen Compliance in the Face of Evolving Import/Export Controls, Economic Sanctions and Regulations

June 11, 2019
  • Philadelphia, PA

With the potential for significant penalties resulting from violations of U.S. sanctions and anti-corruption laws and regulations, ensuring compliance with such laws and regulations is a critical part of conducting business in today’s global economy. Violations can cost companies hundreds of millions of dollars in penalties, a loss of export or government contracting privileges, and reputational damage. For pharmaceutical and medical device companies, an additional risk is the delayed or arrested delivery of life-saving devices and products to patients.

CBI’s Life Sciences Global Trade Summit is the premier forum dedicated to untangling the challenges and discovering the opportunities that life science companies can expect in the changing world of import/export controls, economic sanctions, trade wars and more. Don’t miss this opportunity to hear from regulators and enforcers, learn new approaches from industry experts and gain insights into the future of trade for pharmaceutical and medical device manufacturers

Key Insights and Takeaways:

  • Import/export controls
  • Renegotiation of NAFTA and the Mexico deal
  • US tariffs on China and trade retaliation
  • The potential for a “no-deal” Brexit in March – what does that mean for US? What does that mean for EU?
  • Anti-bribery and anti-corruption
  • How to work effectively with OFAC
  • Conducting due diligence with international vendors
  • Exiting a sanctioned country/gaining an exemption from OFAC

Life Sciences Global Trade Summit

Strengthen Compliance in the Face of Evolving Import/Export Controls, Economic Sanctions and Regulations

With the potential for significant penalties resulting from violations of U.S. sanctions and anti-corruption laws and regulations, ensuring compliance with such laws and regulations is a critical part of conducting business in today’s global economy. Violations can cost companies hundreds of millions of dollars in penalties, a loss of export or government contracting privileges, and reputational damage. For pharmaceutical and medical device companies, an additional risk is the delayed or arrested delivery of life-saving devices and products to patients.

CBI’s Life Sciences Global Trade Summit is the premier forum dedicated to untangling the challenges and discovering the opportunities that life science companies can expect in the changing world of import/export controls, economic sanctions, trade wars and more. Don’t miss this opportunity to hear from regulators and enforcers, learn new approaches from industry experts and gain insights into the future of trade for pharmaceutical and medical device manufacturers

Key Insights and Takeaways:

  • Import/export controls
  • Renegotiation of NAFTA and the Mexico deal
  • US tariffs on China and trade retaliation
  • The potential for a “no-deal” Brexit in March – what does that mean for US? What does that mean for EU?
  • Anti-bribery and anti-corruption
  • How to work effectively with OFAC
  • Conducting due diligence with international vendors
  • Exiting a sanctioned country/gaining an exemption from OFAC